Prof. Matthias Stelljes earned his medical degree in Kiel. He is currently professor of medicine at the University of Muenster and responsible for the adult allogeneic stem cell transplant program at the University Hospital. With more than 160 allogeneic transplants for adult patients per year, the transplant program in Muenster is largest transplant centers in Europe.

Prof. Stelljes is conducting research in the field of T‐cell–mediated immune responses after allogeneic stem cell transplantation. His focus centers on the optimization of treatment strategies for patients with high‐risk/relapsed or refractory hematologic malignancies before and after stem cell transplantation, mainly acute leukemia.

A second area of clinical research focuses on antibody-based treatment strategies for patients with haematological diseases, particularly acute lymphoblastic leukaemia, aiming to optimize front-line therapy as well as treatment of relapsed / refractory disease.

Together with his team, he enrolled substantial numbers of patients in various phase I–III trails, including studies with antiviral drugs, bispecific antibodies / antibody‐drug conjugates, novel approaches in conditioning therapies and GvHD treatment. Prof. Stelljes has published numerous peer‐reviewed papers in journals including Lancet Oncology, Journal of Clinical Oncology, and Blood, either as a main or co‐author.